University Hospital Basel
Basel, 4031, Switzerland
NCT Number: NCT03713242
This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of mild, moderate, and severe hepatic impairment due to liver cirrhosis on the pharmacokinetics of ACT-541468.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 1
Basel, 4031, Switzerland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered as a tablet.
Administered as a tablet.
Time frame: From study treatment administration up to EOS (duration: up to 4 days)
Time frame: From study treatment administration up to EOS (duration: up to 4 days)
Time frame: At various timepoints (duration: up to 4 days)
Time frame: At various timepoints (duration: up to 4 days)
Time frame: At various timepoints (duration: up to 4 days)
Time frame: At various timepoints (duration: up to 4 days)
Time frame: At various timepoints (duration: up to 4 days)
Time frame: At various timepoints (duration: up to 4 days)
Time frame: At various timepoints (duration: up to 4 days)
Idorsia Pharmaceuticals Ltd.
Industry
A Single-center, Open-label, Single-dose, Phase 1 Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06911320
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Orlando, Florida, United States
View Trial DetailsNCT03289234
Healthy, Hepatic Impairment
Fukuoka, Japan
View Trial DetailsNCT04332432
Hepatic Impairment
Rialto, California, United States
View Trial DetailsNCT06736223
Hepatic Impairment
Sofia, Bulgaria
View Trial Details